OptiBiotix Health PLC SlimBiome(R) contract manufacturing agreement (7909I)
06 April 2020 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 7909I
OptiBiotix Health PLC
06 April 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
SlimBiome(R) contract manufacturing agreement with Laboratoire
PYC Inc.
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has
entered into a contract manufacturing agreement with Laboratoire
PYC Inc. ("Laboratoire PYC") in France.
Laboratoire PYC ( https://www.laboratoire-pyc.com/en/company/ )
develops, manufactures and packages private label food supplements,
nutricosmetics and high protein & sport nutrition products.
Laboratoire PYC has more than 30 years of experience and belongs to
the Solina Group ( https://solina-group.com ), a group with a
turnover of approximately EUR450 million. The terms of the
agreement grant Laboratoire PYC the exclusive rights to manufacture
a new type of meal replacement shakes designed specifically to
support the international expansion of OptiBiotix's own label
GoFigure(R) consumer weight management brand.
This is another strategic step by OptiBiotix to de-risk its
supply chain. The deal builds on the recent partnership with Fipros
A/S in Denmark to produce SlimBiome under licence within the
European Union (RNS: 2 April 2020) and creates a source of supply
of GoFigure(R) products located within the European Union to
support the international growth of the B2C brand in Poland (RNS: 6
December 2019), in Malaysia and Singapore (RNS: 6 December 2019)
and Eastern Europe (RNS: 24 March 2020).
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: "We are very pleased to work with
Laboratoire PYC to manufacture a new range of meal replacement
shakes formulated with SlimBiome(R), and sold under the GoFigure(R)
brand. The agreement helps us lower the cost of trade in case of a
hard Brexit, supports our existing and future European
distributors, and builds contingency into the supply chain: a key
requirement from large retail partners who do not want to be
single-sourced. In addition, Laboratoire PYC has a large portfolio
of product formulations which can be formulated with SlimBiome(R)
enabling us to increase the number of applications, extend our
product range, and shorten the development of new GoFigure(R),
SnackSmart(R) and SnackWell(R) products without incurring
significant development costs."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRIJMITMTJMBMM
(END) Dow Jones Newswires
April 06, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024